Non-Group Coverage (Group 1) Coverage for Seniors (Group 66) Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage) Child and Family Services (Group 20403) Alberta Child Health Benefit (Group 20400) Children and Youth Services (Group 19824) Income Support (Group 19823) Alberta Human Services (AISH) (Group 19823) Alberta Adult Health Benefit (AAHB) (Group 23609)
This product is a benefit when prescribed by a Specialist in Infectious Diseases or a designated prescriber.
(Refer to Section 3 - Criteria for Special Authorization of Select Drug Products of the Alberta Drug Benefit List for eligibility when the prescriber prescribing the medication is not a Specialist in Infectious Diseases or a designated prescriber.)
SPECIAL AUTHORIZATION
(Refer to Section 1 - Restricted Benefits of the Alberta Drug Benefit List for coverage of the product when prescribed by a Specialist in Infectious Diseases or a designated prescriber.)
"For treatment of esophageal candidiasis in patients who are resistant or intolerant to fluconazole or itraconazole.
For treatment of invasive candidiasis resistant or intolerant to fluconazole.
For treatment of Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies."*
*Special Authorization is only required when the prescriber prescribing the medication is not a Specialist in Infectious Diseases or a designated prescriber.
Change to Restricted Benefit/Special Authorization
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2005/08/10
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2006/01/01
CDR Recommendation
Review Status
No Special Authorization Criteria Change
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2005/08/10
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2006/01/01
CDR Recommendation
Review Status
No Special Authorization Criteria Change
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2004/02/19
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2005/04/01
CDR Recommendation
Review Status
Special Authorization
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2004/02/19
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2005/01/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2004/02/19
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2005/04/01
CDR Recommendation
Review Status
Special Authorization
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2004/02/19
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2005/01/01
CDR Recommendation
Review Status
Under Review
MERCK CANADA INC. (MFC)
Telephone:(514) 428-7920
Toll-Free:(800) 361-7031
To return to the printable Drug Benefit List and related publications,
click here
Last Updated:
NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.